Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist
摘要:
Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented. (C) 2011 Elsevier Ltd. All rights reserved.
A four-step synthesis of erythro-m-chloro-3-hydroxytyrosine ethyl ester enantiomerically pure
作者:Arlette Solladié-Cavallo、Thomas Nsenda
DOI:10.1016/s0040-4039(98)00172-5
日期:1998.4
configuration, a residue of Vancomycin and Aridicin A, has been prepared in 4 steps using an aldol addition involving a directly generated titaniumenolatederivedfrom a chiraliminoglycinate. (+)-Hydroxypinanone was used as a recoverable chiral auxiliary. The (2S,3S)-erythro isomer will be, of course, available from (−)-hydroxypinanone.
A novel five‐step synthesis of Boc‐3,3‐dimethylglutamic acid α‐ethyl ester 11 is reported. All the steps are high yielding and simple to carry out. By use of the 3,3‐dimethylglutamic acid building block, we successfully discovered a novel class of DPP‐IV inhibitors, Glu‐Pro‐Nitrile dipeptide mimics 2, with high potency (IC50 < 40 nM). The consequence of 3,3‐dimethyl substituent on the rate of intramolecular